Video

Dr. Tripathy Reviews Targeted Therapies in Breast Cancer

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Currently, the HER2-targeted agent trastuzumab is the standard of care for patients with early-stage and metastatic, HER2-positive breast cancer. Newer drugs, Tripathy says, are not perfect but they certainly have a clinical impact. In the first-line setting, the addition of pertuzumab to trastuzumab has shown improvement to disease-free survival and overall survival.

T-DM1, an immunoconjugate targeted at HER2, was recently approved for HER2-positive metastatic breast cancer. This approval was based off an improvement in survival over lapatinib and capecitabine, which was the previous standard of care in the second-line setting for HER2-positive disease.

These advances are important because they extend survival with a minimal impact on toxicity and represent new standard of care, Tripathy notes. However, these agents do have limitations as patients are not cured and not all respond.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center